PT2336184E - Administração de agentes para o tratamento da inflamação - Google Patents

Administração de agentes para o tratamento da inflamação Download PDF

Info

Publication number: PT2336184E
Authority: PT; Portugal
Prior art keywords: inflammation; administration; agents; treatment
Prior art date: 2002-02-25

Application number

PT10012870T

Other languages

English (en)

Inventor

Julie Taylor

Ted A Yednock

Original Assignee

Biogen Idec Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-25

Filing date

2003-02-25

Publication date

2015-03-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2336184(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-02-25 Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc

2015-03-09 Publication of PT2336184E publication Critical patent/PT2336184E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Mycology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Pathology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

PT10012870T 2002-02-25 2003-02-25 Administração de agentes para o tratamento da inflamação PT2336184E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US36013402P	2002-02-25	2002-02-25
US37450102P	2002-04-23	2002-04-23

Publications (1)

Publication Number	Publication Date
PT2336184E true PT2336184E (pt)	2015-03-09

Family

ID=27767592

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT10012870T PT2336184E (pt)	2002-02-25	2003-02-25	Administração de agentes para o tratamento da inflamação
PT03709277T PT1485127E (pt)	2002-02-25	2003-02-25	Administração de agentes para o tratamento de inflamação

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT03709277T PT1485127E (pt)	2002-02-25	2003-02-25	Administração de agentes para o tratamento de inflamação

Country Status (28)

Country	Link
US (7)	US20040009169A1 (pt)
EP (6)	EP3674322A1 (pt)
JP (3)	JP2005526045A (pt)
KR (1)	KR20040105740A (pt)
CN (1)	CN1310678C (pt)
AR (1)	AR038605A1 (pt)
AT (1)	ATE512163T1 (pt)
AU (2)	AU2003213231A1 (pt)
BR (1)	BR0307975A (pt)
CA (1)	CA2477178A1 (pt)
CO (1)	CO5611176A2 (pt)
CY (1)	CY1111787T1 (pt)
DK (2)	DK2336184T3 (pt)
ES (1)	ES2531852T3 (pt)
IL (3)	IL163725A0 (pt)
MX (1)	MXPA04008267A (pt)
MY (1)	MY157727A (pt)
NO (1)	NO336235B1 (pt)
NZ (3)	NZ579583A (pt)
PH (1)	PH12020500242A1 (pt)
PL (1)	PL215263B1 (pt)
PT (2)	PT2336184E (pt)
RU (1)	RU2359697C2 (pt)
SA (1)	SA03240276A (pt)
SI (2)	SI1485127T1 (pt)
TW (2)	TW201125584A (pt)
WO (1)	WO2003072040A2 (pt)
ZA (1)	ZA200407406B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20040105740A (ko)	2002-02-25	2004-12-16	엘란 파마슈티칼스, 인크.	염증 치료제의 투여 방법
MY147019A (en)	2002-03-13	2012-10-15	Biogen Idec Inc	Anti-alpha v beta 6 antibodies
SK50642005A3 (sk) *	2003-01-24	2006-02-02	Elan Pharmaceuticals, Inc.	Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
RU2358763C2 (ru)	2003-02-10	2009-06-20	Элан Фармасьютикалз, Инк.	Композиции иммуноглобулина и способ их получения
UY28391A1 (es)	2003-06-25	2004-12-31	Elan Pharm Inc	Metodos y composiciones para tratar artritis reumatoide
EP1709080B1 (en)	2004-01-09	2011-03-09	Pfizer Inc.	ANTIBODIES TO MAdCAM
EP2394652A3 (en) *	2004-02-06	2012-10-24	Elan Pharmaceuticals Inc.	Methods and compositions for treating tumors and metastatic disease
MY162179A (en) *	2004-04-01	2017-05-31	Elan Pharm Inc	Steroid sparing agents and methods of using same
AU2011213878B2 (en) *	2004-04-01	2012-06-14	Biogen Ma Inc.	Steroid sparing agents and methods of using same
AU2011232775B2 (en) *	2004-08-20	2013-11-28	Biogen Ma Inc.	Extended Treatment of Multiple Sclerosis
CA2478458A1 (en) *	2004-08-20	2006-02-20	Michael Panzara	Treatment of pediatric multiple sclerosis
AU2012202575B2 (en) *	2004-11-19	2014-11-20	Biogen Ma Inc.	Treatment for Multiple Sclerosis
CN101102792A (zh) *	2004-11-19	2008-01-09	比奥根艾迪克Ma公司	治疗多发性硬化
EP1833509A4 (en) *	2004-12-03	2008-12-03	Biogen Idec Inc	DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
DK1835922T3 (da) *	2004-12-22	2009-08-03	Merck Serono Sa	Kombinationsbehandling mod multipel sklerose
PT1848415E (pt) *	2005-02-17	2013-06-27	Teva Pharma	Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
RS56418B2 (sr) *	2005-04-04	2025-01-31	Biogen Ma Inc	Metodi evaluacije imunskog odgovora na terapijsko sredstvo
AU2012202823B2 (en) *	2005-04-04	2014-09-25	Biogen Ma Inc.	Methods and Products for Evaluating an Immune Response to a Therapeutic Protein
CN102875681A (zh)	2005-07-08	2013-01-16	拜奥根Idec马萨诸塞公司	抗-αvβ6抗体及其用途
WO2007007160A2 (en) *	2005-07-11	2007-01-18	Pfizer Limited	Anti-madcam antibodies to treat fever
CA2641160A1 (en) *	2006-02-28	2007-09-07	Elan Pharmaceuticals, Inc.	Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
LT2676967T (lt)	2006-02-28	2019-09-10	Biogen Ma Inc.	Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
BRPI0708392A2 (pt) *	2006-03-03	2011-05-24	Elan Pharm Inc	métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
CN101563105B (zh)	2006-07-10	2013-01-23	拜奥根Idec马萨诸塞公司	用于抑制smad4-缺陷癌症的组合物和方法
WO2008021954A2 (en) *	2006-08-09	2008-02-21	Biogen Idec Ma Inc.	Method for distribution of a drug
US9193790B2 (en)	2006-12-07	2015-11-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
BRPI0901298A2 (pt)	2009-04-06	2011-01-04	Ems Sa	derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
MX2011010971A (es) *	2009-04-17	2012-01-19	Biogen Idec Inc	Composiciones y metodos para tratar leucemia mielogena aguda.
US20120258093A1 (en) *	2009-08-20	2012-10-11	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
ES2666372T3 (es)	2009-10-11	2018-05-04	Biogen Ma Inc.	Ensayos relacionados con anti-VLA-4
EP4524571A3 (en)	2010-01-11	2025-06-11	Biogen MA Inc.	Assay for jc virus antibodies
US11287423B2 (en)	2010-01-11	2022-03-29	Biogen Ma Inc.	Assay for JC virus antibodies
EP4032912B1 (en)	2010-04-16	2025-05-28	Biogen MA Inc.	Anti-vla-4 antibodies
EP3326645B1 (en)	2010-10-25	2020-03-18	Biogen MA Inc.	Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
SG193565A1 (en) *	2011-03-31	2013-11-29	Genentech Inc	Methods of administering beta7 integrin antagonists
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
LT2704742T (lt)	2011-05-02	2017-10-25	Millennium Pharmaceuticals, Inc.	Anti-alfa4beta7 antikūno kompozicija
KR102473834B1 (ko)	2011-05-31	2022-12-02	바이오젠 엠에이 인코포레이티드	Pml의 위험을 판단하는 방법
WO2013105092A1 (en) *	2012-01-12	2013-07-18	Pharma Two B Ltd.	Fixed dose combination therapy of parkinson's disease
EP3666188A1 (en) *	2012-12-05	2020-06-17	Theranos IP Company, LLC	Systems, devices, and methods for bodily fluid sample collection and transport
US10035859B2 (en)	2013-03-15	2018-07-31	Biogen Ma Inc.	Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en)	2013-03-15	2018-07-31	Biogen Ma Inc.	Anti-alpha V beta 6 antibodies and uses thereof
HK1216546A1 (zh)	2013-05-28	2016-11-18	Biogen Ma Inc.	评估pml风险的方法
EP3052189A4 (en) *	2013-10-03	2017-11-01	Leuvas Therapeutics	Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
US9763992B2 (en)	2014-02-13	2017-09-19	Father Flanagan's Boys' Home	Treatment of noise induced hearing loss
DK3127545T3 (da) *	2014-04-04	2020-08-10	Taiho Pharmaceutical Co Ltd	Antitumorlægemiddel, der indeholder taxanforbindelse, og anti- tumorvirkningsfremmer
KR20170005058A (ko) *	2014-05-09	2017-01-11	노그라 파마 리미티드	염증성 장 질환을 치료하는 방법
AR103782A1 (es) *	2015-02-26	2017-05-31	Genentech Inc	ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
CA3002070A1 (en) *	2015-10-16	2017-04-20	Northwestern University	Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
JP2018537536A (ja) *	2015-12-09	2018-12-20	ナントホールディングスアイピーエルエルシーＮａｎｔＨｏｌｄｉｎｇｓＩＰ，ＬＬＣ	Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法
CR20200076A (es)	2017-07-14	2020-06-10	Pfizer	ANTICUERPOS CONTRA MAdCAM
WO2019018688A1 (en) *	2017-07-20	2019-01-24	The University Of Virginia Patent Foundation	METHODS OF TREATING OR PREVENTING A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM
TW202528300A (zh)	2018-04-12	2025-07-16	美商莫菲克醫療股份有限公司	人類整合素α4β7拮抗劑
US20210147547A1 (en) *	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN119080931A (zh)	2018-06-04	2024-12-06	马萨诸塞州渤健公司	具有降低的效应功能的抗vla-4抗体
US20220010019A1 (en) *	2018-11-27	2022-01-13	The General Hospital Corporation	Targeting intraepithelial lymphocytes for treatment of metabolic syndrome
MA57399B1 (fr)	2019-10-16	2025-06-30	Morphic Therapeutic, Inc.	Inhibition de l'intégrine humaine alpha4beta7
WO2022160323A1 (zh) *	2021-01-31	2022-08-04	兰州大学	核苷类似物在制备预防或治疗胃肠道疾病药物中的应用
JP2024513974A (ja)	2021-04-13	2024-03-27	バイオジェン・エムエイ・インコーポレイテッド	慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法
US20240350494A1 (en) *	2021-09-03	2024-10-24	Pliant Therapeutics, Inc.	Therapeutic modulation of integrins
AU2024282654A1 (en)	2023-05-30	2025-12-04	Paragon Therapeutics, Inc.	Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0279582A3 (en)	1987-02-17	1989-10-18	Pharming B.V.	Dna sequences to target proteins to the mammary gland for efficient secretion
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH037237A (ja) *	1989-03-14	1991-01-14	Sandoz Ag	シクロスポリン類投与の新規用途および治療手段
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US5730978A (en)	1989-09-01	1998-03-24	Fred Hutchinson Cancer Research Center	Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL113261A (en)	1989-09-01	1996-10-16	Hutchinson Fred Cancer Res	Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US6033665A (en)	1989-09-27	2000-03-07	Elan Pharmaceuticals, Inc.	Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en)	1989-09-27	1993-11-09	Rubin Lee L	Blood-brain barrier model
SE464961B (sv)	1989-11-15	1991-07-08	Volvo Ab	Ledprotes, i synnerhet foer fingerleder
WO1991007141A1 (de)	1989-11-20	1991-05-30	Wolfgang Becker	Verfahren zur herstellung einer zahnprothese
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
GB9206318D0 (en)	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
US5264563A (en)	1990-08-24	1993-11-23	Ixsys Inc.	Process for synthesizing oligonucleotides with random codons
WO1992015683A1 (en)	1991-03-06	1992-09-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Humanized and chimeric monoclonal antibodies
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
US5224539A (en)	1991-06-14	1993-07-06	Coen Company, Inc.	Cooling system for air heaters and the like
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5872215A (en)	1991-12-02	1999-02-16	Medical Research Council	Specific binding members, materials and methods
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
JPH07506566A (ja)	1992-02-12	1995-07-20	バイオゲン　インコーポレイテッド	炎症性胃腸病の処置
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5336894A (en)	1992-04-21	1994-08-09	The United States Of America As Represented By The Secretary Of The Air Force	Universal infrared heat source controller
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
SG44845A1 (en)	1993-01-12	1997-12-19	Biogen Inc	Recombitant anti-vla4 antibody molecules
DK66493D0 (da) *	1993-06-08	1993-06-08	Ferring A S	Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
AU703152B2 (en)	1994-01-25	1999-03-18	Biogen Ma Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
GB9406974D0 (en)	1994-04-08	1994-06-01	Pharmaceutical Proteins Ltd	Transgenic production
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
WO1996001644A1 (en)	1994-07-11	1996-01-25	Athena Neurosciences, Inc.	Inhibitors of leukocyte adhesion
US6001809A (en)	1994-07-11	1999-12-14	Elan Pharmaceuticals, Inc.	Inhibitors of leukocyte adhesion
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP1281718A3 (en)	1995-11-10	2005-01-19	ELAN CORPORATION, Plc	Peptides which enhance transport across tissues
GB9712818D0 (en)	1996-07-08	1997-08-20	Cambridge Antibody Tech	Labelling and selection of specific binding molecules
IL119989A0 (en)	1997-01-10	1997-04-15	Yeda Res & Dev	Pharmaceutical compositions for oral treatment of multiple sclerosis
ATE441432T1 (de)	1997-03-10	2009-09-15	Ottawa Hospital Res Inst	Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
AU726585B2 (en)	1997-05-29	2000-11-09	Merck & Co., Inc.	Biarylalkanoic acids as cell adhesion inhibitors
JP2002535376A (ja)	1999-01-29	2002-10-22	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	Ｃｃｒ１アンタゴニストを用いた脱髄性炎症性疾患の治療方法
US6387930B1 (en) *	1999-05-04	2002-05-14	Schering Corporation	Piperidine derivatives useful as CCR5 antagonists
US20010046496A1 (en) *	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
EP2287191B1 (en)	2000-05-10	2016-10-12	Mayo Foundation For Medical Education And Research	Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
KR20040105740A (ko)	2002-02-25	2004-12-16	엘란 파마슈티칼스, 인크.	염증 치료제의 투여 방법
SK50642005A3 (sk) *	2003-01-24	2006-02-02	Elan Pharmaceuticals, Inc.	Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
RU2358763C2 (ru) *	2003-02-10	2009-06-20	Элан Фармасьютикалз, Инк.	Композиции иммуноглобулина и способ их получения
US7163939B2 (en)	2003-11-05	2007-01-16	Abbott Laboratories	Macrocyclic kinase inhibitors
EP1833509A4 (en) *	2004-12-03	2008-12-03	Biogen Idec Inc	DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS
US7972775B2 (en) *	2005-03-03	2011-07-05	Seedlings Life Science Ventures, Llc	Method of risk management for patients undergoing Natalizumab treatment
RS56418B2 (sr) *	2005-04-04	2025-01-31	Biogen Ma Inc	Metodi evaluacije imunskog odgovora na terapijsko sredstvo
LT2676967T (lt) *	2006-02-28	2019-09-10	Biogen Ma Inc.	Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu

2003
- 2003-02-25 KR KR10-2004-7013609A patent/KR20040105740A/ko not_active Ceased
- 2003-02-25 PT PT10012870T patent/PT2336184E/pt unknown
- 2003-02-25 PT PT03709277T patent/PT1485127E/pt unknown
- 2003-02-25 ES ES10012870.1T patent/ES2531852T3/es not_active Expired - Lifetime
- 2003-02-25 SI SI200332026T patent/SI1485127T1/sl unknown
- 2003-02-25 TW TW100112502A patent/TW201125584A/zh unknown
- 2003-02-25 CN CNB038091380A patent/CN1310678C/zh not_active Expired - Lifetime
- 2003-02-25 SI SI200332410T patent/SI2336184T1/sl unknown
- 2003-02-25 EP EP19210280.4A patent/EP3674322A1/en not_active Withdrawn
- 2003-02-25 US US10/372,111 patent/US20040009169A1/en not_active Abandoned
- 2003-02-25 DK DK10012870.1T patent/DK2336184T3/en active
- 2003-02-25 MY MYPI20030650A patent/MY157727A/en unknown
- 2003-02-25 BR BR0307975-9A patent/BR0307975A/pt not_active Application Discontinuation
- 2003-02-25 DK DK03709277.2T patent/DK1485127T3/da active
- 2003-02-25 EP EP16195336.9A patent/EP3173426A1/en not_active Ceased
- 2003-02-25 TW TW092103902A patent/TWI346558B/zh not_active IP Right Cessation
- 2003-02-25 NZ NZ579583A patent/NZ579583A/en not_active IP Right Cessation
- 2003-02-25 WO PCT/US2003/005421 patent/WO2003072040A2/en not_active Ceased
- 2003-02-25 EP EP10012870.1A patent/EP2336184B1/en not_active Revoked
- 2003-02-25 NZ NZ535320A patent/NZ535320A/en not_active IP Right Cessation
- 2003-02-25 MX MXPA04008267A patent/MXPA04008267A/es active IP Right Grant
- 2003-02-25 EP EP03709277A patent/EP1485127B1/en not_active Expired - Lifetime
- 2003-02-25 RU RU2004128454/14A patent/RU2359697C2/ru active IP Right Revival
- 2003-02-25 CA CA002477178A patent/CA2477178A1/en not_active Expired - Lifetime
- 2003-02-25 JP JP2003570787A patent/JP2005526045A/ja active Pending
- 2003-02-25 NZ NZ591635A patent/NZ591635A/en not_active IP Right Cessation
- 2003-02-25 EP EP10012871A patent/EP2360185A3/en not_active Withdrawn
- 2003-02-25 AU AU2003213231A patent/AU2003213231A1/en not_active Abandoned
- 2003-02-25 AR ARP030100608A patent/AR038605A1/es not_active Application Discontinuation
- 2003-02-25 IL IL16372503A patent/IL163725A0/xx unknown
- 2003-02-25 PL PL372306A patent/PL215263B1/pl unknown
- 2003-02-25 AT AT03709277T patent/ATE512163T1/de active
- 2003-02-25 EP EP10012872A patent/EP2289941A3/en not_active Withdrawn
- 2003-02-25 PH PH1/2020/500242A patent/PH12020500242A1/en unknown
- 2003-09-02 SA SA03240276A patent/SA03240276A/ar unknown
2004
- 2004-08-25 IL IL163725A patent/IL163725A/en active IP Right Grant
- 2004-09-15 ZA ZA2004/07406A patent/ZA200407406B/en unknown
- 2004-09-24 CO CO04095478A patent/CO5611176A2/es not_active Application Discontinuation
- 2004-09-24 NO NO20044054A patent/NO336235B1/no not_active IP Right Cessation
2006
- 2006-10-02 US US11/540,640 patent/US7807167B2/en not_active Expired - Lifetime
2009
- 2009-04-23 AU AU2009201587A patent/AU2009201587B2/en not_active Expired
2010
- 2010-01-26 IL IL203515A patent/IL203515A/en not_active IP Right Cessation
- 2010-07-29 US US12/846,350 patent/US20110064729A1/en not_active Abandoned
2011
- 2011-01-27 JP JP2011015696A patent/JP2011140493A/ja active Pending
- 2011-08-31 CY CY20111100838T patent/CY1111787T1/el unknown
2014
- 2014-05-23 JP JP2014107437A patent/JP2015042629A/ja active Pending
2015
- 2015-02-04 US US14/613,821 patent/US20150152182A1/en not_active Abandoned
2017
- 2017-05-04 US US15/586,724 patent/US20170306026A1/en not_active Abandoned
2019
- 2019-05-13 US US16/411,042 patent/US11248051B2/en not_active Expired - Lifetime
2022
- 2022-01-18 US US17/578,294 patent/US20220162321A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1485127A4 (en)	2006-02-01
CN1646163A (zh)	2005-07-27
BR0307975A (pt)	2005-01-11
TWI346558B (en)	2011-08-11
CA2477178A1 (en)	2003-09-04
IL203515A (en)	2015-10-29
EP2360185A3 (en)	2012-01-11
JP2015042629A (ja)	2015-03-05
PH12020500242A1 (en)	2023-03-20
US20200148773A1 (en)	2020-05-14
RU2004128454A (ru)	2005-05-10
NO20044054L (no)	2004-11-24
US20220162321A1 (en)	2022-05-26
TW200400047A (en)	2004-01-01
NZ579583A (en)	2011-04-29
NZ535320A (en)	2008-05-30
JP2011140493A (ja)	2011-07-21
JP2005526045A (ja)	2005-09-02
WO2003072040A2 (en)	2003-09-04
ATE512163T1 (de)	2011-06-15
MY157727A (en)	2016-07-15
EP2289941A3 (en)	2012-01-18
US20110064729A1 (en)	2011-03-17
CN1310678C (zh)	2007-04-18
SI2336184T1 (sl)	2015-04-30
RU2359697C2 (ru)	2009-06-27
CY1111787T1 (el)	2015-10-07
CO5611176A2 (es)	2006-02-28
PT1485127E (pt)	2011-09-07
AR038605A1 (es)	2005-01-19
SI1485127T1 (sl)	2011-09-30
EP1485127B1 (en)	2011-06-08
NO336235B1 (no)	2015-06-22
US11248051B2 (en)	2022-02-15
KR20040105740A (ko)	2004-12-16
PL372306A1 (pl)	2005-07-11
US20040009169A1 (en)	2004-01-15
EP3674322A1 (en)	2020-07-01
NZ591635A (en)	2012-06-29
ES2531852T3 (es)	2015-03-20
DK1485127T3 (da)	2011-10-03
HK1073997A1 (en)	2005-10-28
AU2009201587A1 (en)	2009-05-14
EP1485127A2 (en)	2004-12-15
US20170306026A1 (en)	2017-10-26
EP2360185A2 (en)	2011-08-24
EP2336184B1 (en)	2014-12-03
EP2336184A2 (en)	2011-06-22
EP2336184A3 (en)	2012-01-11
SA03240276A (ar)	2005-12-03
AU2003213231A1 (en)	2003-09-09
DK2336184T3 (en)	2015-02-16
US7807167B2 (en)	2010-10-05
IL163725A0 (en)	2005-12-18
PL215263B1 (pl)	2013-11-29
ZA200407406B (en)	2005-11-30
US20150152182A1 (en)	2015-06-04
EP2289941A2 (en)	2011-03-02
WO2003072040A3 (en)	2004-05-21
MXPA04008267A (es)	2004-11-10
TW201125584A (en)	2011-08-01
US20070025989A1 (en)	2007-02-01
IL163725A (en)	2013-07-31
AU2009201587B2 (en)	2012-01-19
EP3173426A1 (en)	2017-05-31

Publication	Publication Date	Title
PT2336184E (pt)	2015-03-09	Administração de agentes para o tratamento da inflamação
PT1605956E (pt)	2016-03-09	Administração de capsaicinóides para o tratamento da osteoartrite
CY2016031I1 (el)	2017-03-15	Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
ITMI20020756A0 (it)	2002-04-09	Composizioni farmaceutiche topiche per il trattamento delle dermatiti
PT1147083E (pt)	2004-09-30	Derivados de arilpiperazinil-ciclohexilindole para o tratamento da depressao
PT1144395E (pt)	2005-08-31	Derivados de 2-aminobenzoxazinona para o tratamento da obesidade
NO20050426L (no)	2005-03-29	Arylkarbonylderivater som terapeutiske midler
PT1143977E (pt)	2005-08-31	Derivados de 2-oxibenzoxazinona para o tratamento da obesidade
NO20053077D0 (no)	2005-06-23	Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
IS7691A (is)	2005-02-09	Lyfjasamsetningar til að meðhöndla æxli
NO20052894D0 (no)	2005-06-14	4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DK1620113T3 (da)	2011-09-12	Topisk formulering af ivermectin til behandling af dermatologiske lidelser
PT1411926E (pt)	2005-10-31	Inibidores de integrina para o tratamento de doencas oftalmicas
CY2018006I1 (el)	2018-06-27	Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
PT1206436E (pt)	2004-12-31	Retinoides para o tratamento de enfisema
PT1150991E (pt)	2004-08-31	Composicoes para o tratamento da resposta inflamatoria
PT1154777E (pt)	2005-07-29	Medicamento para o tratamento de hipertensao arterial
DE60223576D1 (de)	2007-12-27	Hautbehandlungszusammensetzung
NO20043576L (no)	2004-12-22	Pharmaceutical formulation comprising melatonin
PT1286986E (pt)	2005-05-31	Derivados de quinolil-piperidin-4-ilideno-metil-benzamida para o tratamento da dor
DK1553950T3 (da)	2007-10-15	Terapeutisk behandling
DE60222664D1 (de)	2007-11-08	Hautbehandlungsmittel
HK40032312A (en)	2021-03-26	Administration of agents for the treatment of inflammation
NO20042166L (no)	2004-05-25	Kombinasjonsterapi for behandling av sykdom
ITMI20022263A1 (it)	2004-04-26	Composizioni per il trattamento delle emorroidi.